Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials.
Both trandolapril and verapamil are effective and widely used antihypertensive agents. The aim of this study was to estimate the efficacy and tolerability of trandolapril/verapamil (Tr/Ve) combination for blood pressure control and renoprotection. PubMed, EMBASE and Cochrane Library were searched for relevant studies. A meta-analysis of all randomized controlled trials (RCTs) meeting the criteria was performed. Twelve RCTs were ultimately included out of 62 studies. (1) Combination versus trandolapril: a greater diastolic blood pressure (DBP) reduction (weighted mean difference (WMD): 3.71, 95% confidence interval (CI): 1.84-5.57); a greater reduction in albuminuria (WMD: 136.77, 95% CI: 12.44-261.09). There were no differences in reduction in systolic blood pressure (SBP), blood pressure response rate or proteinuria. (2) Combination versus verapamil: a greater SBP reduction (WMD: 6.14, 95% CI: 3.59-8.70); a greater DBP reduction (WMD: 2.49, 95% CI: 0.81-4.17); a greater reduction in proteinuria (standardized mean difference: 0.84, 95% CI: 0.22-1.45); a greater reduction in albuminuria (WMD: 255.00, 95% CI: 119.26-390.74). (3) Incidence of all-cause adverse events (AEs) was comparable between combination and monotherapy. The present meta-analysis indicates that Tr/Ve combination provides a superior blood pressure control and a favourable renoprotective effect without an increase of overall AEs than verapamil monotherapy. The combination also shows a slight advantage over trandolapril monotherapy by reducing DBP and albuminuria to a greater extent.
Zou
Z
Z
Department of Anesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, PR China.
Xu
F-Y
FY
Wang
L
L
An
M-M
MM
Zhang
H
H
Shi
X-Y
XY
D000419:Albuminuria / Q000188:drug therapy; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007211:Indoles; C052035:trandolapril; D014700:Verapamil